Long-term survival after luveltamab tazevibulin, a novel folate receptor-α (FRα) targeting antibody drug conjugate (ADC) in children with CBFA2T3::GLIS2 acute myeloid leukemia (AML). (ASCO 2025) - Apr 23, 2025 - Abstract #e22007; P1/2 | "Luvelta alone or in combination with AML chemotherapy could achieve MRD negativity in more than one third of CBF/GLIS2 AML patients, allowing transplant and resulting survival of more than 2 years. Additional children have received luvelta through compassionate use since 2023 and the pivotal phase 1/2 trial for these patients is now open and enrolling (clinicaltrials.gov NCT06679582)."
Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • CBFA2T3 • FOLR1 • GLIS2
|
|
Robin Williams; Lane Miller; Stephanie Massaro; Elizabeth Krieger; Melinda Pauly; Catherine Nelson; Rebecca Johnson; Jennifer Welch; Deepa Bhojwani; Babak Moghimi; Philip Neff; Terzah Horton; Hamayun Imran; Raul Ribeiro; Terri Guinipero; Felipe Bautista; Matthew Kutny; Amy Johnson; Karen Lewing; Soheil Meshinchi
|